Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
INO's Cash to Debt is ranked higher than
96% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 45.69 vs. INO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
INO' s Cash to Debt Range Over the Past 10 Years
Min: 0.97  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.76
INO's Equity to Asset is ranked higher than
60% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INO: 0.76 )
Ranked among companies with meaningful Equity to Asset only.
INO' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.8 Max: 0.95
Current: 0.76
0.44
0.95
Interest Coverage No Debt
INO's Interest Coverage is ranked higher than
95% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 2.58
M-Score: -2.65
WACC vs ROIC
17.05%
-296.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -208.60
INO's Operating margin (%) is ranked lower than
59% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. INO: -208.60 )
Ranked among companies with meaningful Operating margin (%) only.
INO' s Operating margin (%) Range Over the Past 10 Years
Min: -651  Med: -321.72 Max: -84.5
Current: -208.6
-651
-84.5
Net-margin (%) -199.63
INO's Net-margin (%) is ranked lower than
60% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. INO: -199.63 )
Ranked among companies with meaningful Net-margin (%) only.
INO' s Net-margin (%) Range Over the Past 10 Years
Min: -618.02  Med: -316.04 Max: -71.94
Current: -199.63
-618.02
-71.94
ROE (%) -38.57
INO's ROE (%) is ranked lower than
53% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. INO: -38.57 )
Ranked among companies with meaningful ROE (%) only.
INO' s ROE (%) Range Over the Past 10 Years
Min: -152.12  Med: -46.91 Max: -20.35
Current: -38.57
-152.12
-20.35
ROA (%) -31.04
INO's ROA (%) is ranked lower than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: -29.98 vs. INO: -31.04 )
Ranked among companies with meaningful ROA (%) only.
INO' s ROA (%) Range Over the Past 10 Years
Min: -98.97  Med: -32.88 Max: -16.89
Current: -31.04
-98.97
-16.89
ROC (Joel Greenblatt) (%) -858.18
INO's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 916 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. INO: -858.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7552.88  Med: -3809.2 Max: -576.69
Current: -858.18
-7552.88
-576.69
Revenue Growth (3Y)(%) 69.90
INO's Revenue Growth (3Y)(%) is ranked higher than
92% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. INO: 69.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -81.2  Med: -6.85 Max: 163.7
Current: 69.9
-81.2
163.7
EBITDA Growth (3Y)(%) -9.10
INO's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. INO: -9.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.1  Med: -16.8 Max: 14.1
Current: -9.1
-34.1
14.1
EPS Growth (3Y)(%) -8.80
INO's EPS Growth (3Y)(%) is ranked lower than
56% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. INO: -8.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
INO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.2  Med: -9.65 Max: 27.9
Current: -8.8
-28.2
27.9
GuruFocus has detected 3 Warning Signs with Inovio Pharmaceuticals Inc $INO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INO's 10-Y Financials

Financials (Next Earnings Date: 2017-03-14)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

INO Guru Trades in Q4 2015

Jim Simons 392,781 sh (New)
Joel Greenblatt 37,123 sh (New)
Paul Tudor Jones Sold Out
» More
Q1 2016

INO Guru Trades in Q1 2016

Paul Tudor Jones 50,305 sh (New)
Jim Simons Sold Out
Joel Greenblatt Sold Out
» More
Q2 2016

INO Guru Trades in Q2 2016

Paul Tudor Jones 26,801 sh (-46.72%)
» More
Q3 2016

INO Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:MESO, NAS:IMMU, NAS:OTIC, NAS:NTLA, NAS:CERS, NAS:BCRX, NAS:PTCT, NAS:CYTK, NAS:AVDL, NAS:PACB, OTCPK:ZLDPF, NAS:CTMX, NAS:NK, NAS:RETA, NAS:MCRB, NAS:VSAR, NAS:RGNX, NAS:ATRA, NAS:ASND, NAS:OMER » details
Traded in other countries:GBMB.Germany,
Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.

Inovio Pharmaceuticals Inc was originally incorporated on June 29, 1983, under the laws of California as Biotechnologies & Experimental Research, Inc. The entity changed its corporate name to BTX, Inc. on December 10, 1991, and Genetronics, Inc. on February 8, 1994. On April 14, 1994, the board of directors approved a share exchange agreement with Consolidated United Safety Technologies Inc. On September 2, 1997, it listed on the Toronto Stock Exchange as Genetronics Biomedical Ltd, under the laws of British Columbia, Canada, which wholly owned Genetronics, Inc. On June 15, 2001, it completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation, a Delaware corporation. On January 17, 2003, Genetronics voluntarily de-listed from the Toronto Stock Exchange. On March 31, 2005, its corporate name changed from Genetronics Biomedical Corporation to Inovio Biomedical Corporation. On June 1, 2009, it completed the acquisition of VGX Pharmaceuticals, Inc. ('VGX'), a privately-held company, pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009 by and among Inovio, Inovio's wholly-owned subsidiary Inovio Acquisition, LLC and VGX (the 'Merger'). Upon the closing of the Merger, Inovio Acquisition, LLC assumed all of VGX's business, properties and assets and assumed its obligations, changed its name to VGX Pharmaceuticals, LLC, and remains a wholly-owned subsidiary of the Company, utilizing a single, integrated management team with Inovio. On May 14, 2010, the entity changed its corporate name to Inovio Pharmaceuticals, Inc. The Company is engaged in the development of a new generation of vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. Its DNA-based SynCon technology is designed to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with its proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Its preclinical development and clinical programs include cervical dysplasia/cancer (therapeutic), influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. The Company faces competition from several development-stage and established enterprises, including pharmaceutical and biotechnology firms, which are actively engaged in infectious disease and cancer vaccine research and development. Any pharmaceutical products that the Company develops will require regulatory clearances prior to clinical trials and additional regulatory approvals prior to commercialization. The Company's clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive),

Ratios

vs
industry
vs
history
P/B 3.16
INO's P/B is ranked higher than
52% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.62 vs. INO: 3.16 )
Ranked among companies with meaningful P/B only.
INO' s P/B Range Over the Past 10 Years
Min: 0.38  Med: 2.66 Max: 13.19
Current: 3.16
0.38
13.19
P/S 13.83
INO's P/S is ranked lower than
58% of the 682 Companies
in the Global Biotechnology industry.

( Industry Median: 10.89 vs. INO: 13.83 )
Ranked among companies with meaningful P/S only.
INO' s P/S Range Over the Past 10 Years
Min: 1.5  Med: 15.67 Max: 74.29
Current: 13.83
1.5
74.29
Current Ratio 3.39
INO's Current Ratio is ranked lower than
57% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. INO: 3.39 )
Ranked among companies with meaningful Current Ratio only.
INO' s Current Ratio Range Over the Past 10 Years
Min: 0.82  Med: 3.88 Max: 16.04
Current: 3.39
0.82
16.04
Quick Ratio 3.39
INO's Quick Ratio is ranked lower than
55% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. INO: 3.39 )
Ranked among companies with meaningful Quick Ratio only.
INO' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 3.88 Max: 16.04
Current: 3.39
0.82
16.04
Days Sales Outstanding 194.30
INO's Days Sales Outstanding is ranked lower than
89% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 62.07 vs. INO: 194.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
INO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.24  Med: 69.76 Max: 194.3
Current: 194.3
6.24
194.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.00
INO's 3-Year Average Share Buyback Ratio is ranked lower than
75% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. INO: -26.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -45.3  Med: -31.7 Max: -12
Current: -26
-45.3
-12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.48
INO's Price/Net Cash is ranked lower than
55% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.31 vs. INO: 6.48 )
Ranked among companies with meaningful Price/Net Cash only.
INO' s Price/Net Cash Range Over the Past 10 Years
Min: 2.18  Med: 8.63 Max: 288
Current: 6.48
2.18
288
Price/Net Current Asset Value 5.03
INO's Price/Net Current Asset Value is ranked higher than
52% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. INO: 5.03 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.99  Med: 7.36 Max: 115.2
Current: 5.03
1.99
115.2
Price/Tangible Book 3.62
INO's Price/Tangible Book is ranked higher than
54% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. INO: 3.62 )
Ranked among companies with meaningful Price/Tangible Book only.
INO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.44  Med: 4.79 Max: 20.92
Current: 3.62
1.44
20.92
Price/Median PS Value 0.88
INO's Price/Median PS Value is ranked lower than
51% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. INO: 0.88 )
Ranked among companies with meaningful Price/Median PS Value only.
INO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.02 Max: 52.63
Current: 0.88
0.23
52.63
Earnings Yield (Greenblatt) (%) -20.80
INO's Earnings Yield (Greenblatt) (%) is ranked lower than
71% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. INO: -20.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -20.8  Med: 0 Max: 0
Current: -20.8
-20.8
0

More Statistics

Revenue (TTM) (Mil) $32.79
EPS (TTM) $ -0.91
Beta1.95
Short Percentage of Float16.33%
52-Week Range $4.50 - 11.69
Shares Outstanding (Mil)74.06

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 32 27 24 55
EPS ($) -0.97 -1.24 -1.30 -0.91
EPS w/o NRI ($) -0.97 -1.24 -1.30 -0.91
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for INO

Headlines

Articles On GuruFocus.com
Inovio CEO Invests in 250,000 Shares of Company Stock Aug 13 2014 
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
Weekly CFO Buys Highlight: ZBB, INO, LPR, PMC, FGP, PRMW Jun 17 2012 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 

More From Other Websites
Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US :... Jan 05 2017
Inovio Pharmaceuticals, Inc. – Value Analysis (NASDAQ:INO) : December 27, 2016 Dec 27 2016
Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US :... Dec 26 2016
Inovio Rises on Positive Zika Vaccine Results in First Human Study Dec 21 2016
Inovio Zika vaccine evokes robust response in early human study Dec 21 2016
Inovio's Zika vaccine evokes robust response in human study Dec 21 2016
Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study Dec 21 2016
Inovio’s Zika Vaccine Generates Robust Immune Responses in First Human Study Dec 21 2016
ETFs with exposure to Inovio Pharmaceuticals, Inc. : December 19, 2016 Dec 19 2016
The Unassuming Industry Set to Benefit From President Obama’s Final Move? Dec 16 2016
[$$] Labs Moved Fast After Zika Outbreak Dec 15 2016
Zika Virus Threat Pushes DNA Vaccines Forward Dec 15 2016
Inovio MERS Vaccine Program Gets Cash Infusion (INO) Dec 07 2016
Inovio MERS Vaccine Development to be Expanded with Funding from International Vaccine Institute Dec 06 2016
Inovio Wins $6.1M Zika Drug Development Grant (INO) Dec 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)